From Dealroom · · 40s
Signet Therapeutics Gets China Life Funding for Series A
Signet Therapeutics secures China Life lead investment for Series A extension.
In brief
Signet Therapeutics secures China Life lead investment for Series A extension. Signet Therapeutics closed a Series A extension with China Life Equity Investment to advance its oncology pipeline and heart/kidney disease programs. Originally reported by Dealroom.
Series A Extension Closed
Signet Therapeutics closed first tranche of Series A extension worth several hundred million yuan led by China Life Equity Investment.
AI Organoid Drug Development
Signet builds organoid disease models matching patients' genomic traits and uses AI to screen drug candidates for efficiency.
Key Programs in Progress
SIGX1094 targets diffuse gastric cancer as first FAK/SRC dual-target inhibitor; SIGX2649 is a pan-TEAD inhibitor advancing in pipeline.
Here's the gist
Signet Therapeutics closed a Series A extension with China Life Equity Investment to advance its oncology pipeline and heart/kidney disease programs.
